Joseph Ross
@jsross119
Primary care physician/health policy research @YaleMed; @NCSP_Yale; healthy skeptic; @JAMA_current ed; open science: @YODAProject @Yale_CRRIT @medrxivpreprint
ID: 185653786
http://medicine.yale.edu/intmed/people/joseph_ross-1.profile 01-09-2010 14:25:45
11,11K Tweet
5,5K Followers
1,1K Following
From 2010 to 2024, health care data breaches increased, largely due to hacking or IT incidents, with ransomware attacks increasingly impacting patient records. ja.ma/3YJxO8W Joseph Ross
So proud of our CRRIT Yale School of Medicine students & NCSP at Yale fellows for presenting their research projects on the evidence underlying U.S. FDA approvals, FDA safety actions, costs of care, drug pricing, & more at #SGIM25! SGIM Joseph Ross Reshma Ramachandran
WDRB News Katrina Nickell "Ransomware Attacks and Data Breaches in US Health Care Systems jamanetwork.com/journals/jaman…" by Joseph Ross et al.
While half of the information sources cited in NORD rare-disease reports are not publicly available, access to scholarly journal publications has improved over time. ja.ma/4kxEaAI Joseph Ross
Beautiful evening celebrating Dr. Reshma Ramachandran, recipient of The Bernard Lown Award for Social Responsibility for her work promoting equitable access to medicines, mobilizing physicians nationwide to challenge pharmaceutical industry influence, and advancing legislative reforms
Truly honored to receive the Bernard Lown Award for Social Responsibility from the Lown Institute. Dr. Lown's persistence & ability to mobilize the public against injustice are lessons I will carry forward as we continue to fight for a health system centered around our patients.
With John Xuefeng Jiang, Ph.D. Eli Broad Prof. Joseph Ross, our study JAMA Network Open: Ransomware Attacks and Data Breaches in US Health Care Systems Health care PHI data breaches surged from 2010 to 2024, driven by hacking or IT incidents, particularly ransomware attacks. Johns Hopkins Carey Business School Johns Hopkins Bloomberg School of Public Health
How will the court's decision in ACLA vs FDA affect the future of public health? In JAMA Health Forum, Joseph Ross Reshma Ramachandran and I from Yale CRRIT explore the history of LDT regulation and the implications for future U.S. FDA policy (1/10)
(1/12) New in JAMA Internal Medicine: we assess the performance of U.S. FDA's Breakthrough Devices Program across its first 8 years, with a focus on: ⏲️ Review times 💡Innovation 📊 Evidence CC: Joseph Ross Reshma Ramachandran Harlan Krumholz James Johnston
This is an excellent article that explains these issues, and the ongoing assault on the FDA, and the perspectives of people like Reshma Ramachandran who have pushed to reform the FDA in their work but who are now fighting to save it from these depredations. nytimes.com/2025/07/08/mag…
Surrogate markers are increasingly being used to support U.S. FDA drug approvals instead of measuring clinical outcomes. In a new Federation of American Scientists🔬 memo, Reshma Ramachandran Joshua D. Wallach & Joseph Ross outline how FDA can make transparent & strengthen their evidence. fas.org/publication/va…
High brand-name drug prices fall once a generic enters the market. In a new JGIM Journal of General Internal Medicine article, Ravi Gupta, CRRIT Co-Director Joseph Ross, and colleagues from Program On Regulation, Therapeutics, And Law assess associations between patents, revenue, and generic competition.
Delighted to share my 1st publication in JAMA Health Forum, exploring the patient safety implications of U.S. FDA-regulated, AI-enabled medical devices: jamanetwork.com/journals/jama-… Our study finds AI devices, especially those developed by publicly traded companies, are significantly
